You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases
SBC: BIOSTRATAGIES LC Topic: NICHDMucopolysaccharidosis Type IVA (MPS-IVA; also called Morquio A Syndrome) is a rare genetic childhood disorder characterized by multi-systemic pathologies affecting the respiratory, cardiovascular, musculoskeletal, and central nervous systems leading to devastating quality-of-life and early death. The disease is due to deficiencies in N-acetylgalactosamine-6-sulfate sulfatase (GALNS) causing progre ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Custom Sensor Manufacturing and Regulatory Preparation Assistance for Novel Intraoperative Ureter Detection Device
SBC: BRITESEED, LLC Topic: NICHDPROJECT SUMMARY/ABSTRACT The goal of this small business innovation research grant is to commercialize a cost-effective and contrast-free intraoperative ureter detection system, which integrates into a laparoscopic vessel sealing device to identify ureters in real-time and prevent iatrogenic injuries. 70% of iatrogenic ureteral injuries are detected postoperatively, up to 30 days after hospital di ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A proprietary digital platform for precision patient identification and enrollment of clinical trials for rare kidney diseases
SBC: Nephropathology Associates, PLC Topic: 400Project Summary The goal of this Direct to Phase II program is to develop and test the efficacy of a Precision Medicine Clinical Trials Enrollment Platform for kidney diseases. Approximately half of randomized controlled trials do not meet their recruiting target. Enrolling trials targeting rare kidney diseases is particularly challenging with many conditions subject to stratification and sub-typi ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
GMP Manufacturing and IND Enabling Studies of Extended-Release PNA5: ANovel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular
SBC: Proneurogen, Inc Topic: NIAVascular contributions to cognitive impairment and dementia (VCID) and Alzheimer’s disease related dementias (ADRD) significantly contribute to the 47 million people world-wide who suffer with dementia. This number is estimated to increase to over 130 million people by 2050. Several studies have shown that VCID and conversion to ADRD are strongly correlated with vascular disease, inflammation an ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Production of Natural Deoxysugars for Use in Chemical Synthesis of Glycosides
SBC: MIDWEST BIOPROCESSING CENTER LLC Topic: 300Project SummaryThe goal of the proposal presented herein is to produce naturally occurring 6-deoxysugars, including di- and tri-deoxysugars, amino sugars and branched-chain sugars. These specialized hexoses are found as important structural components throughout plant and microbial secondary metabolites, often playing a crucial role in conferring activity in bioactive natural products, such as ant ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Implantable Microarray Probe for Real-Time Glutamate and GABA Detection
SBC: ALCORIX CO Topic: 105Project Summary This STTR proposal will focus on developing and testing a novel, first-on-the-market implantable biosensor for in vivo, real-time sensing of gamma-aminobutyric acid (GABA) and glutamate (GLU) for animal studies. GABA and GLU are neurotransmitters (NTs) that are essential for information processing and plasticity, memory, and other functions. GLU is the major excitatory NT and GABA ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Quasi-Conformal Ionized PVD Coatings Using HiPIMS Deposition And Etching For Complex 3D Additive Manufacturing Refractory Alloys
SBC: STARFIRE INDUSTRIES LLC Topic: AF224D014This D2P2 program plans to explore a new refractory coating technology to successfully coat additively manufactured (AM) C103 components that exhibit variability in surface roughness, 3D geometrical complexity and build orientation with precision-engineer
SBIR Phase II 2023 Department of DefenseAir Force -
VECSEL Based NV Diamond Magnetometry for Brain Machine Interfacing
SBC: CThru Lasers Inc. Topic: AF224D028Recent interest in high sensitivity magnetic sensing has spurred the development of several technologies, but none are ideal for Magnetoencephalography (MEG) imaging systems. The development of engineered diamonds with defects such as NV centers has been
SBIR Phase II 2023 Department of DefenseAir Force -
Neurosessments: Developing a quick, objective motor test to prompt cognitivetesting in primary care
SBC: NEUROSESSMENTS LLC Topic: NIAPROJECT SUMMARY/ABSTRACT Alzheimer’s disease (AD) is the leading cause of dementia in the United States, affecting one out of every nine older adults. However, Alzheimer’s disease and related dementias (AD/ADRD) can be difficult to diagnose, with physicians missing nearly half of all probable dementia cases. Rates of missed diagnosis are even higher among Black older adults. The majority of ph ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Low-Cost, High-Precision Actuator for Collaborative Autonomy Aircraft
SBC: Kaney Aerospace, Inc. Topic: AFX20DTCSO1Kaney is transitioning MAGTORQUE™ technology for platforms within the Air Force’s Next Generation Air Dominance (NGAD) program. Kaney’s disruptive MAGTORQUE™ technology provides enhanced actuator precision via the strategic integration of magnetic materials to achieve zero backlash actuation, however this zero-backlash actuation requires additional magnetic materials that impact overall ac ...
STTR Phase II 2023 Department of DefenseAir Force